Brief: Oasmia Pharmaceutical: Outcome Of Strategic Review To Deliver Long-Term, Profitable Growth As A Specialty Pharma Company
13/05/2020 09:19
May 13 (Reuters) - Oasmia Pharmaceutical AB OASM.ST :
* ANNOUNCES OUTCOME OF STRATEGIC REVIEW TO DELIVER
LONG-TERM,
PROFITABLE GROWTH AS A SPECIALTY PHARMA COMPANY
* WILL UNDERTAKE A COMPREHENSIVE COST CONTROL PROGRAM
* KEY ASPECTS OF THE COST CONTROL PROGRAM INCLUDE:
ANNUALISED COST
SAVINGS OF MORE THAN SEK 100 MILLION
* KEY ASPECTS OF THE COST CONTROL PROGRAM INCLUDE: ABOUT 50%
REDUCTION IN THE CASH BURN RATE TO BELOW SEK 10 MILLION A MONTH
* KEY ASPECTS OF COST CONTROL PROGRAM INCLUDE: GREATER FOCUS
ON
RESEARCH AND DEVELOPMENT AND CLINICAL TRIAL GMP MANUFACTURING AS
OPPOSED TO COMMERCIAL MANUFACTURING
Source text for Eikon: ID:nNDL2kt6J
Further company coverage: OASM.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))